AB0748 ARE ANY DIFFERENCES BETWEEN JIA - ASSOCIATED UVEITIS, DEVELOPED BEFORE AND AFTER JOINT MANIFESTATION

Background: Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA). Usually uveitis developed during first two years after occurred [1]. In previous studies was shown shorter time interval between and severe course observed [2]. Information about before scarce. Objectives: We aimed to evaluate clinical features therapy JIA-associated uveitis, which joint manifestation. Methods: retrospective study 191 pediatric autoimmune included. The onset age ranged from 1 17 years. evaluated differences in clinical, laboratorial treatment groups, i) where (n=58) ii) (n=133) arthritis. Chronic without manifestations excluded. Results: Uveitits 58 (30.4%) cases. Patients whom had were elder characterized equal gender involvement, rare ANA positivity, use immunosupression, e.g. corticosteroids, biologics methotrexate, due by ophthalmologist predominantly. received earlier severity (LogRank test, p=0.016, HR=1.97 (95%CI: 1.3; 3.1, p=0.004). Data are Table Figure 1. Conclusion: with JIA associated initial ocular presentation demonstrated more delayed diagnostics lack contacts rheumatologist. Cooperation rheumatologist strictly required all cases chronic anterior uveitis. Parameter p Sex, female 32 (55,2) 97 (72,9) 0.016 Onset age, 6.7 (4.6; 10.2) 3.2 (2; 6.1) 0.000001 category Oligoarthritis 41 (70.7) 84 (63.6) 0.174 Polyarthritis 9 (15.5) 36 (27.3) Enthesytis-related 8 (13.8) 12 (9.1) Type Anterior 44 (75.9) 111 (84.1) 0.315 Peripheral 3 (5.2) 2 (1.5) Posterior (2.3) Panuveitis 16 (12.1) Unilateral n (%) 19 (32.8) 48 (36.1) 0.632 posititivity, 25/54 (46.3) 72/110 (65.5) 0.019 HLA B27 8/35 (22.9) 13/62 (21.0) 0.828 Methotrexate, 57/132 (43.2) 0.0000001 Systemic 44/131 (33.6) 0.00003 Biologic, 26 (44.8) 88 (66.2) 0.006 ESR, mm/h 19.0 (4.0; 25.0) 23 (15.0; 32.0) 0.095 CRP, mg/l 97.0 (0.1; 107.5) 8.1 (0.9; 57.4) 0.493 Time 2.7 4.3) 4.0 (2.0; 7.1) biologic, 2.5 3.5) 1.3 (0.5; 5.0) 0.462 This work supported Russian Foundation for Basic Research (grant № 18-515-57001). References: [1]Verazza S, et al. Pediatr Rheumatol Online J 2008;6(Suppl 1):77. [2]Zannin ME, Acta Ophthalmol 2012;90:91-5. Disclosure Interests: None declared